Evidence map›Paper›PMID 33136513›Full record

ReviewCirculation2020

Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction.

Jennifer E Ho, Margaret M Redfield, Gregory D Lewis, Walter J Paulus, Carolyn S P Lam

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 4 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Immunology of heart failure with preserved ejection fraction.Expert review of clinical immunology · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Jennifer E HoCorrigan Minehan Heart Center (J.E.H., G.D.L.), Massachusetts General Hospital, Harvard Medical School, Boston.
Margaret M RedfieldDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (M.M.R.).
Gregory D LewisCorrigan Minehan Heart Center (J.E.H., G.D.L.), Massachusetts General Hospital, Harvard Medical School, Boston.
Walter J PaulusAmsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, The Netherlands (W.J.P.).
Carolyn S P LamNational Heart Centre Singapore (C.S.P.L.).
Harvard University · USAmsterdam University Medical Centers · NLMayo Clinic · USUniversity Medical Center Groningen · NL

Funding

Eicosanoid Profiles as Determinants of HFpEFR01HL140224 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HO, JENNIFER E · 2018 to 2021
$3.1M
The Association of Metabolic Disease and Pulmonary HypertensionR01HL134893 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HO, JENNIFER E · 2017 to 2021
$2.9M
NHLBI NIH HHS R01 HL134893NHLBI NIH HHS R01 HL140224
6 · The paper itself

Abstract

There is a lack of consensus on how we define heart failure with preserved ejection fraction (HFpEF), with wide variation in diagnostic criteria across society guidelines. This lack of uniformity in disease definition stems in part from an incomplete understanding of disease pathobiology, phenotypic heterogeneity, and natural history. We review current knowledge gaps and existing diagnostic tools and algorithms. We present a simple approach to implement these tools within the constraints of the current knowledge base, addressing separately (1) hospitalized individuals with rest congestion, where diagnosis is more straightforward; and (2) individuals with exercise intolerance, where diagnosis is more complex. Here, a potential role for advanced or provocative testing, including evaluation of hemodynamic responses to exercise is considered. More importantly, we propose focus areas for future studies to develop accurate and feasible diagnostic tools for HFpEF, including animal models that recapitulate human HFpEF, and human studies that both address a fundamental understanding of HFpEF pathobiology, and new diagnostic approaches and tools, as well. In sum, there is an urgent need to more accurately define the syndrome of HFpEF to inform diagnosis, patient selection for clinical trials, and, ultimately, future therapeutic approaches.

Indexed as

AlgorithmsStroke VolumeHeart FailureHumansdiagnosisexercise testheart failure

Identifiers

PMID33136513
PMCPMC7805557
OpenAlexW3095409433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.